Experiences from a Clinical Radiopharmaceutical Laboratory

This seminar will present the portfolio of PET diagnostic and therapeutic radiopharmaceuticals available for both clinical and research programs from Q-TRaCE, Nuclear Medicine at Royal Brisbane and Women’s Hospital.

Q-TRaCE (QLD - The Radiopharmaceutical Centre of Excellence) holds a TGA license (18F-FDG and F-18) and operates under a Quality Management System that aligns work practices to GMP principles. In addition to daily, high activity 18F-FDG batches to supply a variety of public institutions in QLD, the laboratory also produces a variety of Ga-68 radiopharmaceuticals to SE QLD public hospitals. The frequency for manufacture of other F-18 PET radiopharmaceuticals is met but dependent on clinical and research requests. Lu-177 radiopharmaceuticals to support peptide receptor radionuclide therapy (PRRT) patient cycles at RBWH occurs weekly, and most recently this has expanded to also include 177LuPSMA-617. All radiopharmaceutical products are subject to pharmacopoeia-standard quality control, prior to release for patient injection.

New product validation is required to provide confidence in product quality and process reliability to implement new radiopharmaceuticals suitable for use in humans. An overview of this site process will also be presented along with some of the new radiopharmaceuticals and process optimisations being implemented at Q-TRaCE throughout 2018.